Patients with stage II to III HER2-positive breast cancer have good outcomes with the combination of neoadjuvant chemotherapy and HER2-targeted agents. A study published by van der Voort et al in The Lancet Oncology investigated whether the duration of this chemotherapy could be tailored on the basis of radiological response.
